Top Line: Can today’s multicancer early-detection (MCED) testing solve more problems than it creates?
The Study: Everyone–particularly investors–is buzzing about the UK’s prospective randomized NHS-Galleri trial. It impressively randomized 142,250 adults ages 50–77 to +/- three annual rounds of the Galleri MCED testing. MCED did not achieve the primary endpoint of reducing the incidence of stage III/IV cancers among 12 prespecified cancer types. However! There was a signal of lowering stage IV cancer incidence (IRR 0.86; 95% CI, 0.74–1.00). About 1% of participants had a positive test in each screening round, and of the 1,801 participants with a positive result, 52% ultimately received a cancer diagnosis. More than 90% of true positive tests correctly mapped to the first or second predicted organ, mitigating the feared “diagnostic odyssey.” MCED notably shifted the route to diagnosis, with more screening-detected and fewer clinically-detected cancers, including 21% fewer diagnoses following emergency presentation. What’s not to love? The test is unsurprisingly substantially more sensitive to more advanced disease—the opposite of what we ideally want from a screening test: more cures with minimal treatment, not more lead-time awareness of a fatal illness. What’s more, downstream psychological and diagnostic costs remain front of mind when half of patients with a positive result have nothing confirmed on subsequent testing.
TBL: MCED is looking increasingly plausible but may prove most meaningfully beneficial in selected patients with concerning symptoms of elusive etiology or those at high risk for cancers with no other available effective screening. | Sasieni, N Engl J Med 2026
The Study: Everyone–particularly investors–is buzzing about the UK’s prospective randomized NHS-Galleri trial. It impressively randomized 142,250 adults ages 50–77 to +/- three annual rounds of the Galleri MCED testing. MCED did not achieve the primary endpoint of reducing the incidence of stage III/IV cancers among 12 prespecified cancer types. However! There was a signal of lowering stage IV cancer incidence (IRR 0.86; 95% CI, 0.74–1.00). About 1% of participants had a positive test in each screening round, and of the 1,801 participants with a positive result, 52% ultimately received a cancer diagnosis. More than 90% of true positive tests correctly mapped to the first or second predicted organ, mitigating the feared “diagnostic odyssey.” MCED notably shifted the route to diagnosis, with more screening-detected and fewer clinically-detected cancers, including 21% fewer diagnoses following emergency presentation. What’s not to love? The test is unsurprisingly substantially more sensitive to more advanced disease—the opposite of what we ideally want from a screening test: more cures with minimal treatment, not more lead-time awareness of a fatal illness. What’s more, downstream psychological and diagnostic costs remain front of mind when half of patients with a positive result have nothing confirmed on subsequent testing.
TBL: MCED is looking increasingly plausible but may prove most meaningfully beneficial in selected patients with concerning symptoms of elusive etiology or those at high risk for cancers with no other available effective screening. | Sasieni, N Engl J Med 2026